<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05058144</url>
  </required_header>
  <id_info>
    <org_study_id>20.23.NR</org_study_id>
    <nct_id>NCT05058144</nct_id>
  </id_info>
  <brief_title>Novel Alpha-Glucan Metabolism</brief_title>
  <official_title>Randomised, Placebo-controlled and Acute Study to Investigate the Metabolism of a Novel Alpha-Glucan in Adults</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Nestlé</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Nestlé</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      These are the characteristics of the project:&#xD;
&#xD;
      Monocentric:&#xD;
&#xD;
      Double blind randomized and crossover: you will test all the 3 products in random order.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study will be randomized, double blind, placebo-controlled, single-center, and 3x3&#xD;
      crossover in design. Eligible participants will be randomized to receive the below products&#xD;
      in single dose and in different random sequence, as determined by the randomization system&#xD;
&#xD;
        1. 50 g novel alpha glucan&#xD;
&#xD;
        2. 50 g (rapidly digestible control)&#xD;
&#xD;
        3. 15 g (dietary fiber)&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">August 30, 2021</start_date>
  <completion_date type="Anticipated">January 30, 2022</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <intervention_model_description>3X3</intervention_model_description>
    <primary_purpose>Other</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Glucose concentration post ingestion of a test product</measure>
    <time_frame>180 minutes</time_frame>
    <description>postprandial glycemic response</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>insuline resonse post ingestion of a test product</measure>
    <time_frame>180 minutes</time_frame>
    <description>postprandial insuline response</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>intestinal hydrogen production as measured by breath hydrogen</measure>
    <time_frame>240 minutes</time_frame>
    <description>postprandial breath hydrogen</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">15</enrollment>
  <condition>Healthy Volunteers</condition>
  <arm_group>
    <arm_group_label>novel alpha glucan</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>50g novel alpha glucan dissolved in 300ml water</description>
  </arm_group>
  <arm_group>
    <arm_group_label>glucose syrup</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>50g dissolved in 300ml water</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Inulin</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>15g Inulin dissolved in 300ml water</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Drinkable solution</intervention_name>
    <description>the volunteer will consume the volume 300 ml of water with</description>
    <arm_group_label>Inulin</arm_group_label>
    <arm_group_label>glucose syrup</arm_group_label>
    <arm_group_label>novel alpha glucan</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        Healthy status (based on anamnesis) Body mass index (BMI) between 18.5 and 29.9 kg/m2 Able&#xD;
        to understand and sign informed consent form.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Pregnant or lactating women&#xD;
&#xD;
          2. Type I and type 2 diabetes&#xD;
&#xD;
          3. Known food allergy or intolerance to test product&#xD;
&#xD;
          4. Major medical/surgical event in the last 3 months potentially interfering with study&#xD;
             procedures and assessments&#xD;
&#xD;
          5. Abnormal bowel transit, history of a gastrointestinal disorder (e.g., inflammatory&#xD;
             bowel disease, diverticular diseases, colon cancer), or history of chronic&#xD;
             constipation with passage of fewer than 3 spontaneous bowel movements per week on&#xD;
             average or chronic or recurrent diarrhea with spontaneous bowel movements more often&#xD;
             than 3 times daily&#xD;
&#xD;
          6. Any concomitant medication potentially interfering with study procedures and&#xD;
             assessment: such as antibiotics, antiacids, or other medications impacting transit&#xD;
             time, colonoscopy, irrigoscopy or other bowel cleansing procedures four weeks prior&#xD;
             the test&#xD;
&#xD;
          7. Recent episode of an acute gastrointestinal illness&#xD;
&#xD;
          8. Alcohol intake higher than 2 servings per day. A serving is 0.4 dl of strong alcohols,&#xD;
             1 dl of red or white wine, or 3 dl of beer.&#xD;
&#xD;
          9. Smokers&#xD;
&#xD;
         10. Volunteer who cannot be expected to comply with the protocol&#xD;
&#xD;
         11. Family or hierarchical relationships with Clinical Innovation Lab team&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>nathalie piccardi, Phd</last_name>
    <phone>+41 21 785-9510</phone>
    <email>nathalie.piccardi@rdls.nestle.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Frederik Delodder, Msc</last_name>
    <phone>079 860 20 86</phone>
    <email>frederik.delodder@rdls.nestle.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Clinical Innovation Lab</name>
      <address>
        <city>Lausanne</city>
        <country>Switzerland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Nathalie Piccardi</last_name>
    </contact>
  </location>
  <location_countries>
    <country>Switzerland</country>
  </location_countries>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>June 24, 2021</study_first_submitted>
  <study_first_submitted_qc>September 16, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">September 27, 2021</study_first_posted>
  <last_update_submitted>September 16, 2021</last_update_submitted>
  <last_update_submitted_qc>September 16, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 27, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

